Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Bullboard Posts
Post by Steve888on Jan 22, 2017 3:00pm
170 Views
Post# 25738986

RE: Cheap shares won't last long

RE: Cheap shares won't last longGet on the boat at current share price of 0.04-0.045, I can sleep easy even with a few cents up or down.

ICO has enough cash for to last close to 1.5 years without dilution.  Think about that? It means that if anyone can buy the stock at say 4 or 5 cents and if it goes up even once in 1.5 years he has made money. Is that simple and clear?

I personally like the odds especially with the events and news thats to come anytime from now on.

Cash and equivalent $2.643 million without debts at the end of September 2016. 

"After the third quarter end, we also announced a world-wide exclusive option to a novel glaucoma candidate and we continue to discuss further complimentary additions to our ophthalmology pipeline with multiple parties. We estimate our runway to extend to Q2 2018 based on the current burn rate and we expect to report additional milestones during the remainder of 2016 and in early 2017". stated Andrew Rae, President and CEO (quoted from the financial report released in November 24, 2016).

Do your own d.d.


Bullboard Posts